The estimated Net Worth of Backer Marianne De is at least $15.6 Milion dollars as of 3 April 2024. Marianne De owns over 72,995 units of Arrowhead Pharmaceuticals stock worth over $14,206,890 and over the last 5 years he sold ARWR stock worth over $1,430,978. In addition, he makes $0 as Independent Director at Arrowhead Pharmaceuticals.
Sign up
Marianne Backer ARWR stock SEC Form 4 insiders trading
Marianne has made over 8 trades of the Arrowhead Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 72,995 units of ARWR stock worth $690,533 on 3 April 2024.
The largest trade he's ever made was selling 72,995 units of Arrowhead Pharmaceuticals stock on 3 April 2024 worth over $690,533. On average, Marianne trades about 4,750 units every 81 days since 2020. As of 3 April 2024 he still owns at least 678,457 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Marianne De stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Marianne De Backer biography
Dr. Marianne De Backer Ph.D. serves as Independent Director of the Company. Dr. De Backer brings over 25 years of experience in healthcare, biotechnology, innovation, strategy, business and corporate development. She has served as member of the Executive Committee, Executive Vice President and Head of Strategy, Business Development and Licensing of Bayer AG (BAYRY) Pharmaceuticals division since 2019. She is also on the board of directors of Gladstone Foundation and Ecohealth Alliance, and on the advisory board of BIOCOM Bay Area and Stanford-Bayer for Digital. From 1991 through 2019 she was at Johnson & Johnson where she most recently held global Business and Corporate Development roles including the position of Vice President of M&A Operations and Divestitures globally for the Pharmaceuticals Group and head of Infectious Diseases & Vaccines Business Development. Prior to that she led a commercial business unit in Europe as well as drug discovery research in both Europe and the United States. Dr. De Backer holds an MBA from Erasmus University Rotterdam, a Master’s degree in Molecular Biology and Biotechnology from Vrije Universiteit Brussels, and a Master’s degree in Engineering and a PhD in Biotechnology from Ghent University.
How old is Marianne Backer?
Marianne Backer is 51, he's been the Independent Director of Arrowhead Pharmaceuticals since 2019. There are 14 older and 3 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.
What's Marianne Backer's mailing address?
Backer's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158.
Insiders trading at Arrowhead Pharmaceuticals
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone a Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
What does Arrowhead Pharmaceuticals do?
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
What does Arrowhead Pharmaceuticals's logo look like?
Complete history of Marianne De stock trades at Arrowhead Pharmaceuticals, Vir Biotechnology Inc a Kronos Bio
Arrowhead Pharmaceuticals executives and stock owners
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Christopher Anzalone,
President, Chief Executive Officer, Director -
Kenneth Myszkowski,
Chief Financial Officer -
Dr. Christopher R. Anzalone,
CEO, Pres & Director -
Patrick O'Brien,
General Counsel -
Kenneth A. Myszkowski,
Chief Financial Officer -
Dr. Javier San Martin M.D.,
Chief Medical Officer -
Dr. Javier San Martin,
Chief Medical Officer -
Douglass Given,
Chairman of the Board -
Michael Perry,
Lead Independent Director -
James Hassard,
Chief Commercial Officer -
Dr. Bruce D. Given,
Advisor -
William Waddill,
Independent Director -
Mauro Ferrari,
Independent Director -
Vincent Anzalone,
IR Contact Officer -
Oye Olukotun,
Independent Director -
Marianne De Backer,
Independent Director -
Javier San Martin,
Chief Medical Officer -
James Hassard,
Chief Commercial Officer -
Curt Bradshaw,
Chief Scientific Officer -
Dr. Mark Seefeld,
Head of Toxicology & VP -
Dr. James C. Hamilton,
Sr. VP of Discovery & Translational Medicine -
Patrick O'Brien,
Chief Compliance Officer, Gen. Counsel & Corp. Sec. -
Howard Lovy,
Director of Communications -
Jane Davidson,
Head of HR & Admin., VP and Corp. Sec. -
Dr. Mark M. Davis,
Founder and Founder & Director of Insert Therapeutics Inc & Calando -
Bruce D Given,
Chief Operating Officer -
Edward W Frykman,
Director -
David M Knott,
10% owner -
Douglas B Given,
Director -
David L. Lewis,
Chief Scientific Officer -
Joseph Theodore Iii Kingsley,
Chief Financial Officer -
Zhen Li,
Snr. VP, Chem and Non-Clin Dev -
Peter Brian Leone,
VP, Strategy & Program Mgmt -
Victoria Vakiener,
Director -
Leon Ekchian,
President -
Marshall Robert Ching,
10% owner -
James M Jr Phillips,
Secretary -
Charles Mc Kenney,
Director -
R Bruce Stewart,
President -
Leroy T Rahn,
Director -
Paul Clayton Mc Donnel,
Chief Financial Officer -
James C Hamilton,
Chief Discovery/Trans Medicine -
Hongbo Lu,
Director -
Tracie Oliver,
Chief Commercial Officer